An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Neuilly-sur-seine, France, 92521
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patient, >/= 18 years of age
- Metastatic breast cancer
- 1st-line treatment with Herceptin initiated in 2002
- Included in pharmaco-epidemiologic HERMINE study
Exclusion Criteria:
- Patient died before scheduled follow-up visit (March 2005)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Median Overall Survival
Time Frame: Up to 7 years
|
The time between the first infusion of trastuzumab and the date of death from any cause.
Participants who were still alive at the end of the post-HERMINE study or lost to follow-up were censored at the last date they were known to be alive.
|
Up to 7 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Median Time to Progression-Free Survival
Time Frame: Up to 7 years
|
The Progression-Free Survival (PFS) was defined as the time between the treatment start date (date of the first trastuzumab infusion) and the date of the first disease progression or disease-related death.
Participants who had not progressed at the end of the post-HERMINE study were censored at the last date they were known to be alive.
Progression-Free Survival was estimated by using Kaplan-Meier method.
|
Up to 7 years
|
|
Median Time to Progression
Time Frame: Up to 7 years
|
The Time to Progression (TTP) was defined as the time between the treatment start date (date of the first trastuzumab infusion) and the date of the first disease progression or disease-related death.
Participants who had not progressed at the end of the post-HERMINE study were censored at the last date they were known to be alive.
If the cause of death was unknown, the death was considered for this analysis as due to the disease.
All participants who did not progress, the death was considered to be due to the disease.
|
Up to 7 years
|
|
Median Treatment Duration and the Duration of Exposure to Trastuzumab
Time Frame: Up to 7 years
|
Treatment duration was defined as the time between the first and the last infusion of trastuzumab.
Exposure duration was defined only for the participants who continued trastuzumab after HERMINE study, as the sum of treatment duration as part of HERMINE study and of the treatment durations as part of post-HERMINE study taking into account temporary treatment discontinuations.
For analyses of treatment and exposure duration , dates of infusion of trastuzumab were missing for 18 participants, so treatment and exposure durations were calculated for only 202 participants.
|
Up to 7 years
|
|
Prognostic Factors for Overall Survival
Time Frame: Up to 7 years
|
Search for prognostic factors for OS was performed using Cox regression model.
First, all parameters were analyzed in univariate models, and the hypothesis of proportional risks was tested.
Significant parameters at 15%-level were retained for the multivariate model.
For the multivariate analysis, two models were built for prognostic factors for OS.
In the first one (Model 1), a stepwise selection method was used on all parameters that were significant in the univariate analyses, whatever the significance level of the associations between parameters.
In the second one (Model 2), a stepwise selection was used on the significant parameters that were not correlated.
The significance level for entry was 10% and the significance level for removal was 5%.
The variables n°5 and n°6 were found to be significantly associated, thus only the variable n°6 was tested in the Model 2. This variable was not retained by the stepwise selection in the Model 1, contrary to the variable n°5.
|
Up to 7 years
|
|
Prognostic Factors For Time to Progression
Time Frame: Up to 7 years
|
Prognostic factors for TTP were searched by using Cox regression model.
First, all parameters were analysed in univariate models, and the hypothesis of proportional risks was tested.
Significant parameters at 15% level were retained for multivariate model.
For multivariate analyses, 2 models were built for prognostic factor of TTP.
In Model 1, stepwise selection method was used on all parameters that were significant in the univariate analyses, whatever the significance level of the associations between parameters.
In Model 2, stepwise selection was used on the significant parameters that were not correlated.
The significance level for entry was 10% and the significance level for exit was 5%.
Six parameters remained in the Model 1 to search for prognostic factors of TTP.
Once the correlated variables were removed, there were only 3 variables left in Model 2: the age was not kept by the stepwise selection.
Results below are for Model 1 and similar results were obtained for Model 2
|
Up to 7 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML22958
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.